PDCD1 and neoplasm: Interestingly, preclinical studies have evaluated the combination of FGFR inhibitors and anti-Programmed cell death protein 1 (PD-1) agents showing enhanced tumoricidal effect by enhancing anti-tumor immune activation [44].